Immunotherapy of melanoma

Giorgio Parmiani, Chiara Castelli, Licia Rivoltini, Chiara Casati, Glenn A. Tully, Luisa Novellino, Andrea Patuzzo, Diego Tosi, Andrea Anichini, Mario Santinami

Research output: Contribution to journalArticlepeer-review


The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma.

Original languageEnglish
Pages (from-to)391-400
Number of pages10
JournalSeminars in Cancer Biology
Issue number6
Publication statusPublished - Dec 2003


  • Adoptive immunotherapy
  • Antigens
  • Melanoma
  • Vaccination

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Immunotherapy of melanoma'. Together they form a unique fingerprint.

Cite this